Efficacy and Safety of Monotherapy with Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study

被引：0
|
作者：
Taylor, Peter C. [1 ]
Schiff, Michael [2 ]
Wang, Qingmin [3 ]
Jiang, Yusang [3 ]
Kurrasch, Regina [4 ]
Daga, Shruti [5 ]
Rao, Ravi [6 ]
Hsu, Benjamin [3 ]
Tak, Paul-Peter [7 ]
机构：
[1] Univ Oxford, Kennedy Inst Rheumatol, NDORMs, Oxford, England
[2] Univ Colorado, Sch Med, Denver, CO USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Uxbridge, Middx, England
[6] GSK Med Res Ctr, Stevenage, Herts, England
[7] GlaxoSmithKline, Stevenage, Herts, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3222
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study
    Taylor, Peter C.
    Schiff, Michael H.
    Wang, Qingmin
    Jiang, Yusang
    Zhuang, Yanli
    Kurrasch, Regina
    Daga, Shruti
    Rao, Ravi
    Tak, Paul P.
    Hsu, Benjamin
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (05) : 658 - 666
  • [2] Integrated Phase 3 Safety Results of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
    Aletaha, Daniel
    Thorne, Carter
    Schiff, Michael
    Harigai, Masayoshi
    Agarwal, Prasheen
    Rao, Ravi
    Cohen, Christopher
    Cheng, Ben
    Brown, Kurt
    Hsu, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [3] Efficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: Results from a 24 week double-blind phase III study
    Nishimoto, N.
    Miyasaka, N.
    Yamamoto, K.
    Kawai, S.
    Takeuchi, T.
    Azuma, J.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 59 - 59
  • [4] Efficacy and Safety of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
    Aletaha, Daniel
    Bingham, Clifton, III
    Tanaka, Yoshiya
    Agarwal, Prasheen
    Kurrasch, Regina
    Tak, Paul-Peter
    Popik, Sharon
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
    Burmester, Gerd R.
    Lin, Yong
    Patel, Rahul
    van Adelsberg, Janet
    Mangan, Erin K.
    Graham, Neil M. H.
    van Hoogstraten, Hubert
    Bauer, Deborah
    Ignacio Vargas, Juan
    Lee, Eun Bong
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (05) : 840 - 847
  • [6] EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED GLOBAL PHASE 3 STUDY (SIRROUND-T)
    Pile, K.
    Aletaha, D.
    Tanaka, Y.
    Agarwal, P.
    Kurrasch, R.
    Tak, P.
    Popik, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 27 - 27
  • [7] One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Harigai, Masayoshi
    Tamamura, Ryo
    Kato, Yuchi
    Ukyo, Yoshifumi
    Nakano, Toshikazu
    Ota, Takayuki
    Hsu, Benjamin
    Tanaka, Yoshiya
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT (SIRROUND-D)
    Takeuchi, T.
    Thorne, C.
    Karpouzas, G.
    Sheng, S.
    Xu, W.
    Rao, R.
    Fei, K.
    Hsu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A531 - A531
  • [9] A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING UPADACITINIB MONOTHERAPY TO MTX MONOTHERAPY IN MTX-NAIVE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
    van Vollenhoven, R.
    Takeuchi, T.
    Pangan, A. L.
    Friedman, A.
    Mohamed, M. F.
    Chen, S.
    Rischmueller, M.
    Blanco, R.
    Xavier, R. M.
    Strand, V.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S4 - S4
  • [10] Long-term safety and efficacy of tocilizumab (an anti-IL-6 receptor monoclonal antibody) in monotherapy, in patients with rheumatoid arthritis
    Nishimoto, N.
    Miyasaka, N.
    Yamamoto, K.
    Kawai, S.
    Takeuchi, T.
    Azuma, J.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 122 - 122
12345